Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 ...

Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Feb 11 (Reuters) - Shares of videogame engine maker Unity Software (U.N), opens new tab dropped nearly 30% on Wednesday after the company forecast first-quarter revenue below Wall Street expectations, ...

Veradermics, a small biotechnology company looking to develop drugs for hair loss, enjoyed a stunning debut on Wall Street Wednesday. And that’s no bald-faced lie. (Sorry. Not sorry.) Shares of ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...